Physician profile
Justyna Egan
NPI 1205122959
$7,746.81
in general payments reported to CMS, 2019-2025
15 companies · $3,019 in 2025
The $3,019 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $42.03 · 2021: $1,267 · 2022: $959 · 2023: $991 · 2024: $1,185 · 2025: $3,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,146 · Travel and Lodging: $1,042 · Education: $7.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,145.87 |
| Travel and Lodging | $1,042.17 |
| Education | $7.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,682.14 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,475.72 | 2019-2025 | Tryptyr, Precision7, Total30 |
| Sun Pharmaceutical Industries INC. | $1,257.41 | 2021-2024 | Cequa |
| Bausch & Lomb Americas INC. | $1,087.13 | 2022-2025 | Infuse, Miebo, Xiidra |
| Glaukos Corporation | $587.87 | 2021-2025 | Idose |
| Sight Sciences, INC. | $434.13 | 2022-2025 | Tearcare System, Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $332.37 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $251.83 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $156.47 | 2024 | |
| Rxsight INC | $147.03 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Abbvie INC. | $124.73 | 2023 | Lumigan, Alphagan P |
| Coopervision INC. | $90.48 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Kala Pharmaceuticals, INC. | $54.93 | 2021-2022 | |
| Allergan, INC. | $38.99 | 2021 | |
| Oyster Point Pharma, INC. | $25.58 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justyna Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.